Xyctrin Phase III trial misses endpoints

Pharmacyclics (PCYC ) announced at 3:59 that in an international Phase III trial in 401 patients with brain metastases, the combination of its Xcytrin

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE